EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel
It is intended for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer Types
Patients with mental illness significantly more likely to experience premature mortality
A Systematic Analysis of the Global Burden of Disease from 2010 to 2019 Suggests Increase in New Cancer Cases, Cancer Deaths and Disability-Adjusted Life Years
The estimates varied substantially by Sociodemographic Index quintile, highlighting global inequities in cancer burden
Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC
Findings from a multi-basket MyPathway study
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
It also approved gallium Ga 68 gozetotide, a radioactive diagnostic agent for PET of PSMA-positive lesions
EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin
New indication concerns the treatment of adult patients with previously untreated diffuse large B-cell lymphoma
FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum
Efficacy was evaluated using real-world data from the EPIK-P1 study
NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted Therapies in Paediatric and Young Adult Patients with Refractory Cancers
Findings from the NCI-COG Pediatric MATCH screening Protocol
FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable or Metastatic Melanoma
Evidence for efficacy is based on results from the RELATIVITY-047 study
Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Subgroup analysis by PD-L1 combined positive score in KEYNOTE-048 study
Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in Patients with Previously Treated Progressive Classical Kaposi Sarcoma
Findings from the single-arm phase II study
EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR Cancers and to Metastatic Cervical Cancer with PD-L1 CPS ≥1
New indications concern the treatment of patients with MSI-H or dMMR advanced colorectal, endometrial, gastric, small intestine, or biliary cancers, and PD-L1-positive metastatic cervical cancer